Levodopa-carbidopa intestinal gel vs Levodopa/carbidopa (ND0612)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Levodopa-carbidopa intestinal gel · Duopa

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Weak signal

NCT00335153 · Phase 3 · completed

This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.

Reported efficacy

Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66) (met)

Result source: NCT00357994

Levodopa/carbidopa (ND0612) · Onerji

Marketed by NeuroDerm Ltd.

Phase 3 in Parkinson's Diseasesmall molecule
Partial signal

NCT02577523 · Phase 2 · completed

Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.

Reported efficacy

Change in Daily "OFF" Time (Baseline to Day 28): Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) (unclear)

Result source: NCT02577523

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLevodopa-carbidopa intestinal gelLevodopa/​carbidopa (ND0612)
OFF time, change-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381
-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505
ON time without troublesome dyskinesia, change4.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381
—Trial running · NCT04006210
UPDRS Part III, change-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387
—Trial running · NCT04006210
MDS-UPDRS Part II, change—Not posted · NCT01960842—Trial running · NCT04006210

OFF time, change

Levodopa-carbidopa intestinal gel
-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381
Levodopa/​carbidopa (ND0612)
-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505

ON time without troublesome dyskinesia, change

Levodopa-carbidopa intestinal gel
4.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210

UPDRS Part III, change

Levodopa-carbidopa intestinal gel
-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210

MDS-UPDRS Part II, change

Levodopa-carbidopa intestinal gel
—Not posted · NCT01960842
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Levodopa-carbidopa intestinal gel: 7 of 7 rows · Levodopa/carbidopa (ND0612): 6 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLevodopa-carbidopa intestinal gel
Rows use multiple source trials
Levodopa/​carbidopa (ND0612)
Rows use multiple source trials
OFF Time
absolute change · hours
No placebo or comparator arm
3.68 hours @ 4wka,b,c
NCT01960842 · Phase 3 · registry result, not featured evidence
-2.8 hours @ 4wk24-hr Infusiond,a,b,c
NCT02577523 · Phase 2
show 1 more dose
-1.3 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
PDQ-39 Summary Index
absolute change · score
No placebo or comparator arm
-10.2 score @ 60wka,b,c,e
NCT01736176 · Phase 3 · registry result, not featured evidence
-7.5 score @ 3.857wk24-hr Infusiond,a,b,c,e
NCT02577523 · Phase 2
show 1 more dose
-3.7 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Total
absolute change · score
-3.6 vs -2.1 Levodopa-Carbidopa Capsules score @ 12wka,b,c,f
NCT00660387 · Phase 3 · registry result, not featured evidence
-11.7 vs -9.3 placebo score @ 2wka,b,c,f
NCT01883505 · Phase 2 · registry result, not featured evidence
Dropout rate
8.5%g
NCT00335153 · Phase 3
show 13 more results
5.4%
NCT00357994 · Phase 3
43.2%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
27.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
33.3%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
15.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
44.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
10.7%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
9.7%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
5.4%
NCT00660387 · Phase 3 · registry result, not featured evidence
37.5%
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
—24-hr Infusionh
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
0%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
1.4%g
NCT00335153 · Phase 3
show 13 more results
2.7%
NCT00357994 · Phase 3
18.9%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
22.7%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
11.1%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
4.4%
NCT02549092 · Phase 3 · registry result, not featured evidence
32.1%
NCT00660673 · Phase 3 · registry result, not featured evidence
3.6%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
3.2%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
2.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
—
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
—24-hr Infusionh
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
—Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
30.5%g
NCT00335153 · Phase 3
show 13 more results
13.5%
NCT00357994 · Phase 3
66.7%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
77.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
77.8%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
20.9%
NCT02549092 · Phase 3 · registry result, not featured evidence
60.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
20.5%
NCT01736176 · Phase 3 · registry result, not featured evidence
12.9%
NCT01960842 · Phase 3 · registry result, not featured evidence
22.6%
NCT00360568 · Phase 3 · registry result, not featured evidence
13.5%
NCT00660387 · Phase 3 · registry result, not featured evidence
16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
0%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
10.5%24-hr Infusionh
NCT02577523 · Phase 2
show 4 more results
10.5%14-hr Infusion
NCT02577523 · Phase 2
5.3%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
g
complication of device insertion 28.8%
abdominal pain 26%
insomnia 18.9%
NCT00335153 · Phase 3
show 13 more results
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00357994 · Phase 3
constipation 22.2%
depression 19.4%
device dislocation 19.4%
NCT00141518 · Phase 4 · registry result, not featured evidence
device dislocation 36.4%
excessive granulation tissue 31.8%
device related infection 27.3%
NCT00141518 · Phase 4 · registry result, not featured evidence
blood homocysteine increased 33.3%
device dislocation 27.8%
constipation 22.2%
NCT00141518 · Phase 4 · registry result, not featured evidence
stoma site pain 14%
abdominal pain 11.6%
stoma site infection 11.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
vitamin b6 decreased 27.1%
blood homocysteine increased 22.5%
postoperative wound infection 21%
NCT00660673 · Phase 3 · registry result, not featured evidence
fall 21.4%
procedural pain 10.7%
abdominal pain 7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
procedural pain 33.3%
stoma site infection 28.2%
stoma site pain 23.1%
NCT01736176 · Phase 3 · registry result, not featured evidence
incision site pain 41.9%
excessive granulation tissue 32.3%
constipation 19.4%
NCT01960842 · Phase 3 · registry result, not featured evidence
incision site erythema 29%
fall 21%
vitamin b6 decreased 21%
NCT00360568 · Phase 3 · registry result, not featured evidence
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
dyskinesia 33.3%
fall 33.3%
anaemia 16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
cold sweat 9.1%
diarrhoea 9.1%
headache 9.1%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
24-hr Infusionh
infusion site nodule 57.9%
infusion site erythema 26.3%
infusion site bruising 21.1%
NCT02577523 · Phase 2
show 4 more results
14-hr Infusion
infusion site nodule 36.8%
infusion site bruising 15.8%
infusion site haemorrhage 15.8%
NCT02577523 · Phase 2
fatigue 10.5% (placebo 0%)
headache 10.5% (placebo 9.1%)
abdominal pain lower 5.3% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
blood creatinine abnormal 12.5% (placebo 0%)
dental caries 12.5% (placebo 0%)
diarrhoea 12.5% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
back pain 12.5% (placebo 0%)
pain in extremity 12.5% (placebo 9.1%)
abdominal pain lower 0% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eAssessment timepoints differ: 60 weeks versus 3.857 weeks.
  6. fAssessment timepoints differ: 12 weeks versus 2 weeks.
  7. gPopulation comparability has not been reviewed for 13 of these studies.
  8. hPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Levodopa-carbidopa intestinal gel

AIMS Total -1.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint; n=317
NCT00335153 · Phase 3
OFF Time -4.44 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-1.3 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time With Td -0.36 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.24 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time Without Td 3.86 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
1.54 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
CGI-I 2.1 score @ 54wk
absolute value · score
No placebo or comparator arm
CGI-I at Endpoint
NCT00335153 · Phase 3
UPDRS I 0 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS II -4.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS Part III -7.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
0.6 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
UPDRS -11.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS IV -3.5 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
PDQ-39 Summary Index -6.9 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.7 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
PDQ-39 Mobility -11.2 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-2.5 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence

+ 329 further endpoints in the CSV export.

Levodopa/carbidopa (ND0612)

Good ON" Time 3.7 hours @ 4wk24-hr Infusion
absolute change · hours
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
2.8 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 3 Motor -19.1 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-10.7 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 2 ADL -2.9 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-1.9 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
CGI-I 52.6% (n=19) @ 0.43wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 10 Participants as posted
show 1 more result
47.4% (n=19) @ 0.43wk*14-hr Infusion
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 9 Participants as posted
CGI-I 73.7% (n=19) @ 4wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 14 Participants as posted
show 1 more result
68.4% (n=19) @ 4wk*14-hr Infusion
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 13 Participants as posted
PDSS-2 -4.1 score @ 3.857wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-0.8 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
PDSS -17.1 vs -0.5 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
PDQ-39 -6.6 vs -1.8 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
CGIC 89.5% (n=19) vs 36.4% (n=11) placebo @ 2wk
event count · % of participants
Improved
NCT01883505 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levodopa-carbidopa intestinal gel's landscape · Levodopa/carbidopa (ND0612)'s landscape